BUDGET IMPACT ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIA

被引：0
|
作者：
Djambazov, S. [1 ]
Slavchev, G. [1 ]
Velchev, M. [2 ]
Vekov, T. [3 ]
机构：
[1] HTA Ltd, Sofia, Bulgaria
[2] Pfizer Luxembourg SARL Branch Bulgaria, Sofia, Bulgaria
[3] Med Univ Pleven, Pleven, Bulgaria
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.135
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN57
引用
收藏
页码：S22 / S22
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Mitova, R.
    Velchev, M.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S31 - S31
  • [2] Patterns and outcomes in HR+/HER2-advanced/metastatic breast cancer patients in Brazil receiving palbociclib
    Simon, Patricia
    Jain, Ankita
    Guarin, Alexandra
    Piton, Luciana
    Carvalho, Carla Fabrine
    Lima, Julia
    Nazareth, Felipe
    FUTURE ONCOLOGY, 2024,
  • [3] Ribociclib in HR+/HER2-Advanced or Metastatic Breast Cancer Patients
    Rascon, Kaitlin
    Flajc, Goran
    De Angelis, Carmine
    Liu, Xinli
    Trivedi, Meghana V.
    Ekinci, Ekim
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (05) : 501 - 509
  • [4] Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study
    Mycock, Katie
    Zhan, Lin
    Hart, Kieran
    Taylor-Stokes, Gavin
    Milligan, Gary
    Atkinson, Christian
    Mitra, Debanjali
    FUTURE ONCOLOGY, 2021, 18 (03) : 349 - 362
  • [5] COST-EFFECTIVENESS OF PALBOCICLIB PLUS LETROZOLE IN THE TREATMENT OF HR+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN ECUADOR
    Cabezas, M.
    Freire, V
    Salcedo, E.
    Albert, A.
    VALUE IN HEALTH, 2018, 21 : S32 - S32
  • [6] Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review
    Wang, Wei
    Wu, Jiayi
    Chen, Keyu
    Wang, Xiaojia
    Shao, Xiying
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [7] Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review
    Wang, Wei
    Wu, Jiayi
    Chen, Keyu
    Wang, Xiaojia
    Shao, Xiying
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [8] NETWORK META-ANALYSIS COMPARING PALBOCICLIB WITH CHEMOTHERAPIES FOR TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR+/ HER2-ADVANCED/METASTATIC BREAST CANCER
    Wilson, F. R.
    Varu, A.
    Mitra, D.
    Cameron, C.
    Iyer, S.
    VALUE IN HEALTH, 2016, 19 (07) : A714 - A714
  • [9] PATIENT REPORTED TREATMENT SATISFACTION WITH PALBOCICLIB COMBINATION THERAPIES FOR HR+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN MULTIPLE COUNTRIES
    Mitra, D.
    Darden, C.
    McSorley, D.
    Davis, K.
    Band, J.
    Iyer, S.
    VALUE IN HEALTH, 2018, 21 : S36 - S36
  • [10] Therapy of HR+/HER2-advanced or metastatic Breast Cancer Palbociclib: Importance of Data from Everyday Care for Therapy
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
12345